Efficacy and Safety of 8-Weeks of Glecaprevir/Pibrentasvir in Treatment-Naive Adults with HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1

被引：0

作者：

Fontana, Robert J. ^{[1
]}

Lens, Sabela ^{[2
,3
]}

McPherson, Stuart ^{[4
,5
]}

Elkhashab, Magdy ^{[6
]}

Katzarov, Krum ^{[7
]}

Pires, Ana Gabriela ^{[8
]}

Xue, Zhenyi ^{[8
]}

Trinh, Roger ^{[8
]}

Rodrigues, Lino, Jr. ^{[8
]}

Porcalla, Ariel ^{[8
]}

Zeuzem, Stefan ^{[9
]}

机构：

[1] Univ Michigan, Div Gastroenterol & Hepatol, Ann Arbor, MI 48109 USA

[2] Idibaps, Hosp Clin, Liver Unit, Barcelona, Spain

[3] Ciberehd, Madrid, Spain

[4] Newcastle Upon Tyne Hosp NHS Fdn & Trust, Liver Unit, Newcastle Upon Tyne, Tyne & Wear, England

[5] Newcastle Univ, Newcastle Upon Tyne, Tyne & Wear, England

[6] Toronto Liver Ctr, Toronto, ON, Canada

[7] Mil Med Acad, Dept Gastroenterol Hepatopancreatobiliary HPB Sur, Belgrade, Serbia

[8] Abbvie Inc, N Chicago, IL USA

[9] Goethe Univ Frankfurt, Frankfurt, Germany

来源：

HEPATOLOGY | 2018年 / 68卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

653

引用

页码：388A / 389A

页数：2

共 50 条

[1] Safety and efficacy of glecaprevir/pibrentasvir for the treatment of HCV genotype 1-6: Results of the HCV-TARGET study
Sterling, Richard
Zeuzem, Stefan
Welzel, Tania
Manns, Michael P.
Reddy, Rajender
Terrault, Norah
Ben Ari, Ziv
Vodkin, Irine
Toor, Arifa
Vainorius, Monika
Akushevich, Lucy
Fried, Michael W.
Nelson, David R.
Sulkowski, Mark
JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E241 - E242
[2] EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR IN TREATMENT-NAIVE ADULTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPES 1-6 IN BRAZIL
Peribanez-Gonzalez, Mario
Cheinquer, Hugo
Rodrigues, Lino
Lima, Maria Patelli J. S.
Alvares-da-Silva, Mario Reis
Madruga, Jose
Parise, Edison
Pessoa, Mario Guimaraes
Furtado, Juvencio
Villanova, Marcia G.
Ferreira, Adalgisa
Mazzoleni, Felipe
Nascimento, Ecio
Lu, Wenjing
Schnell, Gretja
Burroughs, Margaret
Reuter, Tania
HEPATOLOGY, 2019, 70 : 925A - 926A
[3] SAFETY AND EFFICACY OF GLECAPREVIR/PIBRENTASVIR FOR THE TREATMENT OF HCV GENOTYPE 1-6: RESULTS OF THE HCV-TARGET STUDY
Sterling, Richard K.
Zeuzem, Stefan
Welzel, Tania M.
Manns, Michael
Reddy, K. Rajender
Terrault, Norah
Ben-Ari, Ziv
Vodkin, Irine
Toor, Arifa
Vainorius, Monika
Akushevich, Lucy
Fried, Michael W.
Nelson, David R.
Sulkowski, Mark S.
GASTROENTEROLOGY, 2019, 156 (06) : S1220 - S1220
[4] Efficacy and safety of glecaprevir/pibrentasvir in treatment-naive adults with chronic hepatitis C virus genotypes 1-6 in Brazil
Peribanez-Gonzaleza, Mario
Cheinquer, Hugo
Rodrigues, Lino
Lima, Maria Patelli
Alvares-da-Silva, Mario Reis
Madruga, Jose
Parise, Edison Roberto
Pessoa, Mario Guimaraes
Furtado, Juvencio
Villanova, Marcia
Ferreira, Adalgisa
Mazzoleni, Felipe
Nascimento, Ecio
Silva, Giovanni Faria
Fredrick, Linda
Krishnan, Preethi
Burroughs, Margaret
Reuter, Tania
ANNALS OF HEPATOLOGY, 2021, 20
[5] Glecaprevir/pibrentasvir for 8 weeks in treatment-naive patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial
Brown, Robert S., Jr.
Buti, Maria
Rodrigues, Lino
Chulanov, Vladimir
Chuang, Wan-Long
Aguilar, Humberto
Horvath, Gabor
Zuckerman, Elimelech
Carrion, Barbara Rosado
Rodriguez-Perez, Federico
Urbanek, Petr
Abergel, Armand
Cohen, Eric
Lovell, Sandra S.
Schnell, Gretja
Lin, Chih-Wei
Zha, Jiuhong
Wang, Stanley
Trinh, Roger
Mensa, Federico J.
Burroughs, Margaret
Felizarta, Franco
JOURNAL OF HEPATOLOGY, 2020, 72 (03) : 441 - 449
[6] Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naive, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study
Fontana, Robert J.
Lens, Sabela
McPherson, Stuart
Elkhashab, Magdy
Ankoma-Sey, Victor
Bondin, Mark
dos Santos, Ana Gabriela Pires
Xue, Zhenyi
Trinh, Roger
Porcalla, Ariel
Zeuzem, Stefan
ADVANCES IN THERAPY, 2019, 36 (12) : 3458 - 3470
[7] Efficacy and Safety of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Treatment-Naive Patients with Chronic HCV Genotype 3: An Integrated Phase 2/3 Analysis
Flamm, Steven L.
Wyles, David L.
Wang, Stanley
Mutimer, David J.
Rockstroh, Jrgen K.
Horsmans, Yves J.
Kwo, Paul Y.
Weiland, Ola
Villa, Erica
Heo, Jeong
Gane, Edward J.
Ryder, Stephen D.
Welzel, Tania M.
Ng, Teresa
Lovell, Sandra S.
Liu, Ran
Krishnan, Preethi
Kopecky-Bromberg, Sarah
Asatryan, Armen
Trinh, Roger
Mensa, Federico J.
HEPATOLOGY, 2017, 66 : 35A - 36A
[8] EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR IN RENALLY-IMPAIRED PATIENTS WITH CHRONIC HCV GENOTYPE 1-6 INFECTION
Lawitz, Eric
Flisiak, Robert
Abunimeh, Manal
Sise, Meghan
Park, Jun Yong
Kaskas, Marwan
Bruchfeld, Annette
Worns, Marcus-Alexander
Aglitti, Andrea
Xue, Zhenyi
Rullman, Janean
Porcalla, Ariel R.
Cohen, Eric
Trinh, Roger N.
Persico, Marcello
GASTROENTEROLOGY, 2018, 154 (06) : S1104 - S1105
[9] INTEGRATED EFFICACY AND SAFETY ANALYSIS OF GENOTYPES 1-6 TREATMENT-NAIVE, NON-CIRRHOTIC, AND COMPENSATED CIRRHOTIC HISPANIC/LATINO PATIENTS WHO RECEIVED 8 WEEKS OF GLECAPREVIR/PIBRENTASVIR
Gutierrez, Julio A.
Zuckerman, Eli
Dylla, Douglas E.
De Ledinghen, Victor
Muir, Andrew Joseph
Gschwantler, Michael
Puoti, Massimo
Slim, Jihad
Nevens, Frederik
Fredrick, Linda M.
Agront, Nancy
Burroughs, Margaret
HEPATOLOGY, 2020, 72 : 537A - 538A
[10] Preliminary Efficacy and Safety of 8-Week Glecaprevir/Pibrentasvir in Patients with HCV Genotype 1-6 Infection and Compensated Cirrhosis: The Expedition-8 Study
Brown, Robert S., Jr.
Hezode, Christophe
Wang, Stanley
Buti, Maria
Chuang, Wan-Long
Aguilar, Humberto I.
Horvath, Gabor
Rosado-Carrion, Barbara
Rodriguez-Perez, Federico
Cohen, Eric
Hui, Yiran B.
Schnell, Gretja
Lin, Chih-Wei
Rodrigues, Lino, Jr.
Trinh, Roger
Mensa, Federico J.
Felizarta, Franco
HEPATOLOGY, 2018, 68 : 425A - 426A

← 1 2 3 4 5 →